Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2a, 2-part, Randomized, Double-blind, Placebo-controlled, Incomplete Block Crossover Study to Evaluate the Safety and Efficacy of VX-371 Solution for Inhalation With and Without Oral Ivacaftor in Subjects With Primary Ciliary Dyskinesia

Next Previous
Trial Profile

Phase 2a, 2-part, Randomized, Double-blind, Placebo-controlled, Incomplete Block Crossover Study to Evaluate the Safety and Efficacy of VX-371 Solution for Inhalation With and Without Oral Ivacaftor in Subjects With Primary Ciliary Dyskinesia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idrevloride (Primary) ; Ivacaftor
  • Indications Primary ciliary dyskinesia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CLEAN-PCD
  • Sponsors Parion Sciences; Vertex Pharmaceuticals

    • Most Recent Events

    • 08 Sep 2023 According to a Parion Sciences media release, results from this trial will be presented at the European Respiratory Society International Congress 2023 during the Abstracts Leading to Evolution in Respiratory Medicine Trials (ALERT) session.
    • 08 Sep 2023 According to a Parion Sciences media release, positive results from this trial were published in the Lancet Respiratory Medicine.
    • 08 Sep 2023 Results presented in the Parion Sciences Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top